Pain and Inflammation Research

Although separate conditions, pain and inflammation are nearly always associated with each other. Pain is defined by the International Association for the Study of Pain (IASP) as 'an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage'. Inflammation is the tissue's immunologic response to injury, characterized by mobilization of white blood cells and antibodies, swelling, and fluid accumulation.

Pain and Inflammation Research Products Areas

Products for Pain and Inflammation Research - Page 88

Cat.No. Product Name Information/Activity
BCC7901 TCN 238 TCN238 is a positive allosteric mGlu4 receptor modulator with an EC50 of 1 μM.
BCC4596 VU 0361737 VU 0361737 is a selective positive allosteric modulator (PAM) for mGlu4 receptor with EC50 of 240 nM and 110 nM at human and rat receptors, respectively, displays weak activity at mGlu5 and mGlu8 receptors, is inactive at mGlu1, mGlu2, mGlu3, mGlu6 and mGlu7 receptors.
BCC1239 VU 0364439 VU 0364439 is a mGlu4 positive allosteric modulator (PAM), with EC50 of 19.8 nM.
BCC4597 VU 0364770 VU0364770 is a selective and potent positive allosteric modulator (PAM) of mGlu4. VU0346770 exhibits EC50s of 290 nM and 1.1 μM at rat mGlu4 and human mGlu4 receptor, respectively. VU0364770 exhibits antagonist activity at mGlu5 with a potency of 17.9 μM and PAM activity at mGlu6 with a potency of 6.8 μM. VU0364770 also possesses activity at MAO with Ki values of 8.5 and 0.72 μM for human MAO-A and human MAO-B, respectively.
BCC6689 L-NIO dihydrochloride L-NIO dihydrochloride is a potent, non-selective and NADPH-dependent nitric oxide synthase (NOS) inhibitor, with Kis of 1.7, 3.9, 3.9 μM for neuronal (nNOS), endothelial (eNOS), and inducible (iNOS), respectively. L-NIO dihydrochloride induces a consistentfocal ischemic infarctin rats.
BCC6795 Aminoguanidine hydrochloride Aminoguanidine hydrochloride is a diamine oxidase and NO synthase inhibitor, reduces levels of advanced glycation end products (AGEs) through interacting with 3-deoxyglucosone, is an investigational drug for the treatment of diabetic nephropathy.
BCC6823 AMT hydrochloride 21463-31-0
BCC6092 AR-C 102222 253771-21-0
BCC7506 BYK 191023 dihydrochloride Potent and selective inhibitor of iNOS
BCC6824 EIT hydrobromide 1071-37-0